Published in Clin Ther on June 01, 2005
Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother (2012) 0.85
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res (2011) 0.81
Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health (2004) 4.98
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol (2002) 2.54
Birth centers in Australia: a national population-based study of perinatal mortality associated with giving birth in a birth center. Birth (2007) 2.27
Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension (2006) 2.11
GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care (2010) 1.98
Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension (2005) 1.95
Admission of term infants to neonatal intensive care: a population-based study. Birth (2007) 1.77
Maternal mortality and psychiatric morbidity in the perinatal period: challenges and opportunities for prevention in the Australian setting. Med J Aust (2007) 1.76
Does size matter? A population-based study of birth in lower volume maternity hospitals for low risk women. BJOG (2006) 1.76
Stanford presenteeism scale: health status and employee productivity. J Occup Environ Med (2002) 1.74
The assessment of chronic health conditions on work performance, absence, and total economic impact for employers. J Occup Environ Med (2005) 1.67
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res (2002) 1.58
Antihypertensive persistence and drug class. Can J Cardiol (2002) 1.48
International Committee for Monitoring Assisted Reproductive Technology (ICMART) world report: assisted reproductive technology 2003. Fertil Steril (2011) 1.46
Capacity to monitor severe maternal morbidity in Australia. Aust N Z J Obstet Gynaecol (2008) 1.44
Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health (2009) 1.43
World collaborative report on in vitro fertilization, 2000. Fertil Steril (2006) 1.42
Measuring the effects of work loss on productivity with team production. Health Econ (2006) 1.31
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
A general model of the impact of absenteeism on employers and employees. Health Econ (2002) 1.31
Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale? Med Decis Making (2002) 1.28
Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) (2005) 1.25
Valuing reductions in on-the-job illness: 'presenteeism' from managerial and economic perspectives. Health Econ (2008) 1.24
The impact of consumer-directed health plans on prescription drug use. Health Aff (Millwood) (2008) 1.23
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Extracorporeal membrane oxygenation for severe ARDS in pregnant and postpartum women during the 2009 H1N1 pandemic. Intensive Care Med (2011) 1.22
Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care (2005) 1.19
Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth (2012) 1.17
Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluation. Diabetes Care (2003) 1.12
Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf (2005) 1.11
International Committee for Monitoring Assisted Reproductive Technologies world report: Assisted Reproductive Technology 2006. Hum Reprod (2014) 1.10
The ICMART glossary on ART terminology. Hum Reprod (2006) 1.09
Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis (2006) 1.05
How to present the business case for healthcare quality to employers. Appl Health Econ Health Policy (2005) 1.04
Birth outcomes associated with interventions in labour amongst low risk women: a population-based study. Women Birth (2007) 1.03
The National Program of Cancer Registries: explaining state variations in average cost per case reported. Prev Chronic Dis (2005) 1.02
Reliability and validity of the Stanford Presenteeism Scale. J Occup Environ Med (2004) 1.02
Colorectal cancer screening attitudes and practices in the general population: a risk-adjusted survey. J Public Health Manag Pract (2005) 1.00
The International Committee Monitoring Assisted Reproductive Technologies (ICMART) glossary on ART terminology. Fertil Steril (2006) 0.99
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 0.95
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res (2007) 0.94
A randomized controlled open trial of population-based disease and case management in a Medicare Plus Choice health maintenance organization. Prev Chronic Dis (2004) 0.93
Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum (2003) 0.92
Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. Int J Infect Dis (2004) 0.91
An evaluation of a patient-reported outcomes found computerized adaptive testing was efficient in assessing osteoarthritis impact. J Clin Epidemiol (2006) 0.90
Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol (2002) 0.89
Aligning quality for populations and patients: do we know which way to go? Am J Public Health (2003) 0.89
A new national Chlamydia Sentinel Surveillance System in Australia: evaluation of the first stage of implementation. Commun Dis Intell Q Rep (2010) 0.88
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm (2007) 0.87
Maternal deaths in New South Wales, Australia: a data linkage project. Aust N Z J Obstet Gynaecol (2008) 0.87
MotherSafe: review of three years of counselling by an Australian Teratology Information Service. Aust N Z J Obstet Gynaecol (2009) 0.87
Raising the bar of efficacy for drug approval requires an understanding of patient diversity. J Clin Oncol (2010) 0.86
Does infant feeding method impact on maternal mental health? Breastfeed Med (2014) 0.85
Asthma control and patient satisfaction among early pediatric users of montelukast. J Asthma (2002) 0.85
The role of private industry in pragmatic comparative effectiveness trials. J Comp Eff Res (2012) 0.85
Treatment of migraine with rizatriptan: when to take the medication. Headache (2002) 0.83
Getting real performance out of pay-for-performance. Milbank Q (2008) 0.81
The end of the Australia antigen? An ecological study of the impact of universal newborn hepatitis B vaccination two decades on. Vaccine (2012) 0.81
Chemokine receptor CXCR3 desensitization by IL-16/CD4 signaling is dependent on CCR5 and intact membrane cholesterol. J Immunol (2006) 0.81
Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections? Am Surg (2005) 0.80
Do disease management programs for patients with coronary heart disease make a difference? Experiences of nine practices. Am J Manag Care (2002) 0.79
The need to evaluate public health reforms: Australian perinatal mental health initiatives. Aust N Z J Public Health (2012) 0.79
Endogeneity bias in the absence of unobserved heterogeneity. Ann Epidemiol (2004) 0.79
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer. Bioorg Med Chem Lett (2007) 0.79
The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy. Pharmacoeconomics (2006) 0.78
Matrix metalloproteinases in the aneurysm wall of patients treated with low-dose doxycycline. Vascular (2005) 0.78
Maternal mortality: what can we learn from stories of postpartum haemorrhage? Women Birth (2009) 0.78
Provision of support strategies and services: results from an internet-based survey of community-based breastfeeding counselors. J Hum Lact (2012) 0.78
Hospital admissions for alcohol use disorders before, during, and after pregnancy: a study based on linked population data in new South Wales, Australia. Alcohol Clin Exp Res (2013) 0.77
Impact of migraine symptoms on health care use and work loss in Canada in patients randomly assigned in a phase III clinical trial. Can J Clin Pharmacol (2002) 0.77
Growth in use of lipid-lowering therapies: are we targeting the right patients? Am J Manag Care (2002) 0.77
Late-onset Huntington's disease masquerading as normal pressure hydrocephalus. J Neuropsychiatry Clin Neurosci (2009) 0.77
Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective. Can J Cardiol (2004) 0.76
Evidence synthesis and evidence-based decision making: related but distinct processes. Med Decis Making (2005) 0.75
Misaligned incentives in America's health: who's minding the store? Ann Fam Med (2005) 0.75
Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies. Med Care (2016) 0.75
The view of a model user on the ISPOR-SMDM modeling good research task force report. Value Health (2012) 0.75
Predicting the Strength of Anion-π Interactions of Substituted Benzenes: the Development of Anion-π Binding Substituent Constants. J Phys Chem A (2016) 0.75
The decision to conduct a head-to-head comparative trial: a game-theoretic analysis. Med Decis Making (2007) 0.75
Rational formulary decision making: is drug classification rational? Value Health (2003) 0.75
Treatment outcomes in patients receiving conventional amphotericin B therapy: a prospective multicentre study in Taiwan. J Antimicrob Chemother (2006) 0.75